+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

NGS-Based RNA-Sequencing Market by Product, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533389
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The NGS-Based RNA-Sequencing Market is projected to reach USD 3.77 Billion in 2026. It is expected to continue growing at a CAGR of 19.74%, reaching USD 11.20 Billion by 2032.

NGS-based RNA sequencing, often searched as RNA-seq or next-generation RNA sequencing, enables transcriptome profiling by converting RNA into sequencing-ready libraries and aligning reads to reveal gene expression, isoforms, fusions, splice variants, allele-specific expression, and noncoding RNA activity. The technology is central to precision oncology, immunology, infectious disease research, single-cell biology, neuroscience, rare disease investigation, and biomarker discovery.

Adoption is supported by the well-documented decline in sequencing costs, improved library preparation, higher-throughput instruments, cloud bioinformatics, and expanding clinical evidence for transcriptomic biomarkers. Industry demand is strongest where organizations need high-resolution, hypothesis-free analysis that goes beyond targeted assays and supports reproducible discovery across research, translational, and diagnostic workflows.

Transformative Shifts in the RNA-Seq Landscape

The RNA sequencing landscape is shifting from bulk transcriptomics toward single-cell RNA-seq, spatial transcriptomics, long-read RNA sequencing, and multiomics workflows. These approaches help researchers connect gene expression with cell identity, tissue architecture, epigenetic regulation, immune status, and proteomic signals, improving biological interpretation in cancer, neuroscience, immunology, developmental biology, and rare disease studies.

Clinical translation is also accelerating as standardized sample handling, automation, quality-control metrics, external proficiency testing, and validated bioinformatics pipelines reduce variability. At the same time, demand for decentralized sequencing, companion diagnostic development, liquid biopsy research, pathogen transcriptomics, and population-scale transcriptome analysis is reshaping procurement decisions across academic centers, hospitals, contract research organizations, public health laboratories, and biopharma research teams.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer across NGS-based RNA sequencing, especially for read quality control, transcript quantification, splice-event detection, variant interpretation, cell-type annotation, pathway analysis, phenotype prediction, and clinical report drafting. Machine learning models are improving signal detection in noisy datasets and helping prioritize biomarkers from high-dimensional transcriptomic data generated through bulk, single-cell, and spatial sequencing workflows.

The cumulative impact is higher analytical throughput, faster decision-making, and improved consistency in complex transcriptome interpretation, but governance remains essential. Leaders must manage model bias, training-data transparency, explainability, cybersecurity, privacy protection, and regulatory expectations for software used in clinical or research decision support. AI-enabled RNA-seq delivers the most value when paired with curated reference datasets, auditable workflows, human expert review, and validated molecular interpretation standards.

Key Regional Insights

North America remains a leading region for NGS-based RNA sequencing due to strong publicly funded genomics research, advanced cancer centers, established molecular pathology networks, mature biopharma research activity, and a dense ecosystem of sequencing infrastructure, cloud computing, and bioinformatics expertise. The United States anchors demand through precision oncology, rare disease research, immunotherapy development, and public health genomics, while Canada contributes through population genomics, academic research networks, cancer programs, and precision medicine initiatives.

Europe benefits from cross-border research programs, national genomics strategies, biobank infrastructure, cancer research networks, and a strong regulatory emphasis on data protection, clinical evidence, and laboratory quality systems. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, Singapore, and Australia invest in genomics infrastructure, oncology research, infectious disease surveillance, single-cell platforms, and translational medicine. Latin America is strengthening RNA-seq adoption through academic collaborations, oncology studies, infectious disease research, and agricultural biotechnology, with Brazil and Mexico acting as important regional contributors. The Middle East is advancing through national genome programs, precision medicine investments, and modern tertiary hospital networks, especially in Gulf economies. Africa is earlier in adoption but shows rising demand through pathogen surveillance, population genetics, capacity-building programs, cancer research partnerships, and regional laboratory modernization.

Key Group Insights

Within ASEAN, Singapore acts as a regional genomics and biomedical research hub supported by advanced clinical research infrastructure, strong data capabilities, and public-sector investment, while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines are expanding sequencing access through universities, reference laboratories, cancer centers, and public health programs. The GCC is investing in precision medicine, national genome initiatives, newborn and rare disease research, and advanced hospital networks, creating demand for clinical-grade RNA-seq infrastructure, secure bioinformatics, and locally compliant data governance.

The European Union supports RNA sequencing through collaborative research funding, cancer mission programs, rare disease networks, biobanks, and harmonized data-governance frameworks that influence clinical-grade transcriptomics adoption. BRICS markets combine large patient populations, expanding local sequencing capacity, and growing pharmaceutical and academic research activity, although reimbursement, procurement maturity, and data-infrastructure readiness vary by country. G7 countries lead in research intensity, diagnostics adoption, regulatory development, and bioinformatics depth, while NATO member states increasingly view genomics, pathogen surveillance, resilient supply chains, and secure health-data infrastructure as strategic capabilities for public health and biosecurity.

Key Country Insights

The United States leads global commercialization of NGS-based RNA sequencing through academic medical centers, biopharma R&D, precision oncology programs, rare disease research, public health sequencing networks, and sequencing technology innovation. Canada emphasizes research networks, population genomics, cancer research, and equitable access, while Mexico and Brazil are expanding RNA-seq through oncology, infectious disease, microbiology, and agricultural biotechnology research. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong life sciences ecosystems with national genomics, cancer research, biobank programs, and molecular pathology capabilities, while Russia maintains selective genomics capabilities in academic, clinical, and state-backed research institutions.

China has scaled sequencing capacity through hospital networks, domestic genomics infrastructure, government-supported precision medicine programs, oncology research, and population-scale initiatives. India is building momentum through cost-efficient sequencing services, population diversity studies, infectious disease research, cancer genomics, and expanding bioinformatics talent. Japan, South Korea, and Australia show strong demand for clinical research, single-cell RNA sequencing, immunology, neuroscience, oncology, and translational medicine, supported by advanced healthcare systems, biomedical funding, and established academic-industry collaboration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated workflows rather than competing only on sequencing throughput. High-value opportunities include single-cell RNA-seq, spatial transcriptomics, FFPE-compatible assays, liquid biopsy research, long-read transcriptomics, pathogen transcriptomics, immune repertoire analysis, and integrated DNA-RNA panels for oncology, rare disease, and fusion detection applications.

Organizations should invest in automation, sample-quality controls, validated pipelines, secure cloud infrastructure, interoperability, and data standards that support reproducibility across laboratories. Commercial teams should align offerings with clinical evidence, regulatory readiness, reimbursement strategy, laboratory accreditation requirements, and regional data-sovereignty rules. Partnerships with hospitals, contract research organizations, biobanks, public health laboratories, and AI developers can accelerate adoption while reducing operational friction and strengthening trust in RNA-seq results.

Research Methodology

This executive summary is based on secondary research from publicly available and reputable sources, including government genomics programs, peer-reviewed literature, regulatory agency guidance, public health organizations, clinical genomics initiatives, standards bodies, and published biomedical research. The analysis emphasizes verified technology, regulatory, and adoption trends rather than speculative market sizing, market share, or forecasting.

Research inputs were synthesized across technology adoption, regional investment, clinical translation, regulatory maturity, data-governance requirements, end-user demand, and application relevance. The methodology prioritizes triangulation across independent sources, consistency checks, terminology normalization, and relevance to NGS-based RNA sequencing applications in research, diagnostics, pharmaceutical development, precision medicine, and public health surveillance.

Conclusion

NGS-based RNA sequencing is moving from specialized research use toward a broader role in precision medicine, translational research, public health genomics, and data-driven drug development. Its ability to measure transcript-level biology at scale makes it essential for biomarker discovery, immune profiling, tumor characterization, fusion detection, drug response studies, and complex disease research.

The next phase of competition will be defined by workflow reliability, AI-enabled interpretation, regional access, regulatory confidence, data security, and integration with multiomics platforms. Organizations that combine scientific rigor with scalable informatics, validated quality systems, and clinical-grade execution will be best positioned to lead in NGS-based RNA sequencing.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. NGS-Based RNA-Sequencing Market, by Product
7.1. Consumables
7.1.1. Enzymes
7.1.2. Reagents And Kits
7.2. Instruments
7.2.1. Data Analysis Platforms
7.2.2. Library Prep Instruments
7.2.3. Sequencers
7.3. Services
7.3.1. Bioinformatics Analysis Services
7.3.2. Project Management Services
7.3.3. Sample Preparation Services
8. NGS-Based RNA-Sequencing Market, by Technology
8.1. Bulk Sequencing
8.2. Long-Read Sequencing
8.3. Single-Cell Sequencing
8.4. Spatial Transcriptomics
9. NGS-Based RNA-Sequencing Market, by Application
9.1. Biomarker Discovery
9.1.1. Early-Stage Biomarker Identification
9.1.2. Validation
9.2. Drug Discovery & Development
9.2.1. Pharmacokinetic Studies
9.2.2. Target Identification
9.2.3. Toxicology Studies
9.3. Gene Expression Profiling
9.3.1. Bulk Profiling
9.3.2. Single-Cell Profiling
9.3.3. Spatial Profiling
9.4. Personalized Medicine
9.4.1. Companion Diagnostics
9.4.2. Therapeutic Monitoring
10. NGS-Based RNA-Sequencing Market, by End User
10.1. Academic & Government
10.1.1. Research Institutes
10.1.2. Universities
10.2. Clinical Diagnostics Laboratories
10.2.1. Hospital Laboratories
10.2.2. Independent Laboratories
10.3. Contract Research Organizations
10.4. Pharmaceutical & Biotechnology Companies
10.4.1. Biotechnology Companies
10.4.2. Pharmaceutical Companies
11. NGS-Based RNA-Sequencing Market, by Distribution Channel
11.1. Online
11.2. Offline
12. Asia-Pacific NGS-Based RNA-Sequencing Market
13. North America NGS-Based RNA-Sequencing Market
14. Latin America NGS-Based RNA-Sequencing Market
15. Europe NGS-Based RNA-Sequencing Market
16. Middle East NGS-Based RNA-Sequencing Market
17. Africa NGS-Based RNA-Sequencing Market
18. ASEAN NGS-Based RNA-Sequencing Market
19. GCC NGS-Based RNA-Sequencing Market
20. European Union NGS-Based RNA-Sequencing Market
21. BRICS NGS-Based RNA-Sequencing Market
22. G7 NGS-Based RNA-Sequencing Market
23. NATO NGS-Based RNA-Sequencing Market
24. United States NGS-Based RNA-Sequencing Market
25. Canada NGS-Based RNA-Sequencing Market
26. Mexico NGS-Based RNA-Sequencing Market
27. Brazil NGS-Based RNA-Sequencing Market
28. United Kingdom NGS-Based RNA-Sequencing Market
29. Germany NGS-Based RNA-Sequencing Market
30. France NGS-Based RNA-Sequencing Market
31. Russia NGS-Based RNA-Sequencing Market
32. Italy NGS-Based RNA-Sequencing Market
33. Spain NGS-Based RNA-Sequencing Market
34. China NGS-Based RNA-Sequencing Market
35. India NGS-Based RNA-Sequencing Market
36. Japan NGS-Based RNA-Sequencing Market
37. Australia NGS-Based RNA-Sequencing Market
38. South Korea NGS-Based RNA-Sequencing Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. 10x Genomics Inc
40.2. Agilent Technologies Inc
40.3. Becton Dickinson and Company
40.4. BGI Group
40.5. Danaher Corporation
40.6. Eurofins Scientific SE
40.7. F Hoffmann-La Roche Ltd
40.8. Fulgent Genetics Inc
40.9. GenScript Biotech Corporation
40.10. Hamilton Company
40.11. Illumina Inc
40.12. LGC Limited
40.13. MGI Tech Co Ltd
40.14. NeoGenomics Laboratories Inc
40.15. New England Biolabs Inc
40.16. Novogene Co Ltd
40.17. Oxford Nanopore Technologies PLC
40.18. Pacific Biosciences of California Inc
40.19. Promega Corporation
40.20. Psomagen Inc
40.21. QIAGEN N V
40.22. Revvity Inc
40.23. SD Biosensor Inc
40.24. Takara Bio Inc
40.25. Tecan Trading AG
40.26. Thermo Fisher Scientific Inc
40.27. Twist Bioscience Corporation
40.28. WuXi Biologics Cayman Inc
List of Figures
FIGURE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CANADA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. MEXICO NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. BRAZIL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. UNITED KINGDOM NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. SPAIN NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CHINA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL REAGENTS AND KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL REAGENTS AND KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL REAGENTS AND KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LIBRARY PREP INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LIBRARY PREP INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LIBRARY PREP INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BIOINFORMATICS ANALYSIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BIOINFORMATICS ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BIOINFORMATICS ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROJECT MANAGEMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROJECT MANAGEMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROJECT MANAGEMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SAMPLE PREPARATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SAMPLE PREPARATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SAMPLE PREPARATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BULK SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BULK SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BULK SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LONG-READ SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL LONG-READ SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LONG-READ SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SINGLE-CELL SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SINGLE-CELL SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SINGLE-CELL SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SPATIAL TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SPATIAL TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SPATIAL TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL EARLY-STAGE BIOMARKER IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL EARLY-STAGE BIOMARKER IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL EARLY-STAGE BIOMARKER IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PHARMACOKINETIC STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PHARMACOKINETIC STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PHARMACOKINETIC STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENE EXPRESSION PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENE EXPRESSION PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENE EXPRESSION PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BULK PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BULK PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BULK PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SINGLE-CELL PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SINGLE-CELL PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SINGLE-CELL PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL SPATIAL PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SPATIAL PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL SPATIAL PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ACADEMIC & GOVERNMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ACADEMIC & GOVERNMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ACADEMIC & GOVERNMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL UNIVERSITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL UNIVERSITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL UNIVERSITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CLINICAL DIAGNOSTICS LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CLINICAL DIAGNOSTICS LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CLINICAL DIAGNOSTICS LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 185. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 186. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 187. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 188. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 189. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 191. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 192. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 193. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 194. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 195. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 197. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 198. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 199. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 217. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 218. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 219. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 220. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 221. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 222. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 223. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 224. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 225. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 226. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 227. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 229. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 230. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 231. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 233. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 234. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 235. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 236. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 237. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 238. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 239. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 240. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 241. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 242. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 243. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 245. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 246. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 247. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 248. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 249. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 250. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 251. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 252. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 253. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 254. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 255. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 256. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 257. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 258. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 259. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 261. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 262. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 263. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 281. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 282. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 283. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 284. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 285. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 286. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 287. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 288. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 289. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 290. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 291. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 293. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 294. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 295. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 296. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 297. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 298. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 299. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 300. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 301. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 302. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 303. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 304. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 305. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 306. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 307. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 309. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 310. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 311. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 312. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 313. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 314. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 315. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 316. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 317. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 318. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 319. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 320. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 321. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
TABLE 322. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
TABLE 323. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 324. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2032 (USD MILLION)
TABLE 325. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2032 (USD MILLION)
TABLE 326. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
TABLE 327. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 328. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 329. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 330. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
TABLE 331. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 332. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
TABLE 333. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 334. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 335. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
TABLE 336. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
TABLE 337. UNITED STATES NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD

Companies Mentioned

The companies featured in this NGS-Based RNA-Sequencing market report include:
  • 10x Genomics Inc
  • Agilent Technologies Inc
  • Becton Dickinson and Company
  • BGI Group
  • Danaher Corporation
  • Eurofins Scientific SE
  • F Hoffmann-La Roche Ltd
  • Fulgent Genetics Inc
  • GenScript Biotech Corporation
  • Hamilton Company
  • Illumina Inc
  • LGC Limited
  • MGI Tech Co Ltd
  • NeoGenomics Laboratories Inc
  • New England Biolabs Inc
  • Novogene Co Ltd
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California Inc
  • Promega Corporation
  • Psomagen Inc
  • QIAGEN N V
  • Revvity Inc
  • SD Biosensor Inc
  • Takara Bio Inc
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc
  • Twist Bioscience Corporation
  • WuXi Biologics Cayman Inc

Table Information